2023
Systematic review and meta-analysis: Season of birth and schizophrenia risk
Coury S, Lombroso A, Avila-Quintero V, Taylor J, Flores J, Szejko N, Bloch M. Systematic review and meta-analysis: Season of birth and schizophrenia risk. Schizophrenia Research 2023, 252: 244-252. PMID: 36682315, DOI: 10.1016/j.schres.2022.12.016.Peer-Reviewed Original ResearchConceptsRisk of schizophreniaSummer birthWinter birthSystematic reviewBirth monthVitamin D deficiencyStratified subgroup analysisSchizophrenia riskEtiological risk factorsMonth of birthD deficiencySeason of birthEtiologic causesSubgroup analysisVirus exposureRisk factorsSchizophreniaMonthsBirthSignificant differencesRiskAssociation
2021
Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlatesMeta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders
Vankawala J, Naples G, Avila-Quintero VJ, Ramírez KL, Flores JM, Bloch MH, Dwyer JB. Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders. Frontiers In Psychiatry 2021, 12: 549080. PMID: 33841195, PMCID: PMC8024485, DOI: 10.3389/fpsyt.2021.549080.Peer-Reviewed Original ResearchTreatment-resistant depressionSub-anesthetic dosesPost-traumatic stress disorderKetamine treatmentBlood pressureObsessive-compulsive disorderKetamine dosesHemodynamic parametersPsychiatric disordersPsychiatric populationsAverage heart rate increaseKetamine/esketamineStratified subgroup analysisKetamine-induced changesPotential cardiovascular riskHeart rate increaseAdult psychiatric populationSignificant increaseAdult age groupsSub-anesthetic ketamineEsketamine treatmentCardiovascular riskKetamine infusionHemodynamic changesSBP increase
2019
Meta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisordersMeta-Analysis of Placebo Response in Adult Antidepressant Trials
Li F, Nasir M, Olten B, Bloch MH. Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs 2019, 33: 971-980. PMID: 31573058, DOI: 10.1007/s40263-019-00662-y.Peer-Reviewed Original ResearchConceptsPlacebo response ratesPlacebo improvementSymptom improvementObsessive-compulsive disorderResponse rateDiagnostic indicationsAntidepressant trialsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisSecond-generation antidepressantsPlacebo comparison groupFuture antidepressantsSubgroup analysisClinical trialsPlacebo responseTrial characteristicsGreater magnitudeDepression trialsMeta-AnalysisUS sitesTrial durationAntidepressantsLanguage limitsMean difference
2018
Meta-analysis: Second generation antidepressants and headache
Telang S, Walton C, Olten B, Bloch MH. Meta-analysis: Second generation antidepressants and headache. Journal Of Affective Disorders 2018, 236: 60-68. PMID: 29715610, DOI: 10.1016/j.jad.2018.04.047.Peer-Reviewed Original ResearchConceptsRisk of headacheSecond-generation antidepressantsAntidepressant medicationGeneration antidepressantsSide effectsTreatment-emergent side effectsPlacebo-controlled trialPooled risk ratioFixed-dose trialStratified subgroup analysisTreatment of adultsDosage of medicationReceptor affinity profileSignificant differencesMeta-analysis resultsOnly antidepressantsMedication classesMedication dosingMedication typeObsessive-compulsive disorderSubgroup analysisRisk ratioRelative riskHeadacheMedications
2017
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta K, Beyer C, Johnson JA, Bloch MH. Meta-analysis: Risk of dry mouth with second generation antidepressants. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 84: 282-293. PMID: 29274375, DOI: 10.1016/j.pnpbp.2017.12.012.Peer-Reviewed Original ResearchConceptsDry mouthSecond-generation antidepressantsGreater riskAntidepressant agentsGeneration antidepressantsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisReceptor affinity profileSNRI classMedication classesAntidepressant medicationAtypical antidepressantsRisk ratioSubgroup analysisDepressive disorderSTUDY SELECTIONPubMed searchDATA SOURCESSNRIsDiagnostic indicationsSSRIsAntidepressantsAnxiety diagnosesAnxiety disordersEfficacy of antipsychotics for irritability and aggression in children: a meta-analysis
van Schalkwyk GI, Lewis AS, Beyer C, Johnson J, van Rensburg S, Bloch MH. Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis. Expert Review Of Neurotherapeutics 2017, 17: 1045-1053. PMID: 28847182, DOI: 10.1080/14737175.2017.1371012.Peer-Reviewed Original ResearchConceptsDegree of sedationSubgroup analysisDiagnostic indicationsOverall dose effectEfficacy of risperidoneStratified subgroup analysisEfficacy of antipsychoticsIndividual antipsychotic agentsChoice of agentRange of diagnosesSpecific medicationsAntipsychotic efficacyAntipsychotic agentsAntipsychotic doseClinical dataOverall effect sizeAntipsychoticsNegative psychosocial outcomesIrritabilityPsychosocial outcomesEfficacyDiagnosisDose effectSedationRisperidoneMeta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants
Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants. Depression And Anxiety 2017, 34: 1134-1146. PMID: 28881483, DOI: 10.1002/da.22680.Peer-Reviewed Original ResearchConceptsSSRI/SNRI medicationsSerotonin-norepinephrine reuptake inhibitorsSecond-generation antidepressantsAntidepressant medicationSNRI medicationsMost antidepressant medicationsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisTreatment of adultsReceptor affinity profileMedication classesReuptake inhibitorsMedication typeObsessive-compulsive disorderAntidepressant agentsRisk ratioSubgroup analysisDepressive disorderDopamine transporter affinityHyperhidrosisMedicationsPubMed searchSide effectsDopamine transporterRisk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. The Journal Of Clinical Psychiatry 2017, 78: e648-e655. PMID: 28682529, DOI: 10.4088/jcp.15r10601.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisk of irritabilitySide effectsPsychostimulant medicationPsychostimulant treatmentAmphetamine derivativesPlacebo-controlled trialCommon side effectsStratified subgroup analysisEffects of amphetamineTreatment of childrenDuration of usePsychostimulant classesEligible trialsMedical comorbiditiesHead trialsSubgroup analysisRisk ratioRelative riskSTUDY SELECTIONEffective treatmentDATA SOURCESPubMed searchTrial designStimulant type
2015
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder
Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. American Journal Of Psychiatry 2015, 173: 174-183. PMID: 26552940, PMCID: PMC4975858, DOI: 10.1176/appi.ajp.2015.15030331.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsMajor depressive disorderSerotonin reuptake inhibitorsDepressive disorderHigh dosesTreatment responseReuptake inhibitorsBenefit of SSRIsEfficacy of SSRIsTolerability of SSRIsEffects of SSRIsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisTherapeutic dose rangeDose-response relationshipSSRI doseTolerability analysisMedication dosesSignificant positive associationSubgroup analysisMultiple time pointsDose categoriesMixed regression modelsCause dropoutsMeta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2015, 25: 611-617. PMID: 26402485, PMCID: PMC4617411, DOI: 10.1089/cap.2015.0075.Peer-Reviewed Original ResearchConceptsRisk of anxietyAttention-deficit/hyperactivity disorderPsychostimulant treatmentSide effectsHyperactivity disorderPlacebo-controlled trialStratified subgroup analysisTreatment of childrenDuration of useRisk ratioSubgroup analysisPsychostimulant medicationPlaceboPubMed searchTrial designNumber of childrenHigh dosesStimulant typePsychostimulantsAnxiety symptomsTreatmentChildrenRiskSymptomsAnxietyMeta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, Bloch MH. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 728-736. PMID: 26299294, DOI: 10.1016/j.jaac.2015.06.011.Peer-Reviewed Original ResearchConceptsWorsening of ticsRisk of ticsAttention-deficit/hyperactivity disorderPlacebo-controlled trialNew onsetDuration of treatmentPsychostimulant usePsychostimulant medicationNew-onset ticsType of psychostimulantsParallel-group trialStratified subgroup analysisSide effect dataTreatment of childrenAge of participantsPlacebo groupAdverse eventsCrossover studyPsychostimulant treatmentTic symptomsRisk ratioSubgroup analysisFamily historyGroup trialsPubMed search
2012
Systematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder
Gray SM, Bloch MH. Systematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder. Current Psychiatry Reports 2012, 14: 220-228. PMID: 22477442, PMCID: PMC3625952, DOI: 10.1007/s11920-012-0272-0.Peer-Reviewed Original ResearchConceptsIL-6 levelsStratified subgroup analysisTNF-α levelsObsessive-compulsive disorderProinflammatory cytokinesComorbid depressionMedication useIL-6Subgroup analysisCerebrospinal fluid cytokine levelsElevated TNF-α levelsPlasma IL-6 levelsLower plasma IL-6 levelsIL-1β levelsTumor necrosis factorCytokine levelsEffect of ageSerum levelsPsychotropic medicationsPlasma levelsNecrosis factorInclusion criteriaImmune functionPotential confoundingSystematic review
2011
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alpha